Overview

Data as of September 17, 2019 11:08 pm EDT

Press Releases

Summary Toggle Madrigal Pharmaceuticals Reports 2019 Second Quarter Financial Results and Highlights

August 07, 2019

-- Phase 3 MAESTRO-NASH Program Continues to Progress -- -- Jim Daly Added to Board of Directors and Becky Taub Promoted to President of R&D -- -- Madrigal Presentations Selected for the Liver Meeting ® AASLD 2019 in Boston , November 2019 -- CONSHOHOCKEN, Pa. , Aug.
Summary Toggle Madrigal Pharmaceuticals Promotes Rebecca Taub, M.D., Chief Medical Officer and Executive Vice President of Research & Development, to Newly Created Position of President of Research & Development

July 11, 2019

-- Dr. Taub to present at the 5th Paris NASH Meeting to be held on July 11-12, 2019 -- CONSHOHOCKEN, Pa. , July 11, 2019 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today the promotion of Rebecca Taub , M.D., to the newly created positon of President of Research &
Summary Toggle Madrigal Pharmaceuticals Announces Appointment of Jim Daly to Board of Directors

July 02, 2019

CONSHOHOCKEN, Pa. , July 02, 2019 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced that Jim Daly has been appointed to the Company’s Board of Directors, as a Class I director, effective as of June 27 , 2019. “We are extremely pleased to have an executive with Jim’s

Filing date	Form	Description	Filing Group	View
June 13, 2005	RW	Withdrawal of registration statement filed under the Securities Act	Other	0001047469-05-017134.rtf 0001047469-05-017134.xls 0001047469-05-017134.pdf
February 13, 2007	4	Statement of changes in beneficial ownership of securities	3,4,5	0001179110-07-003589.rtf 0001179110-07-003589.pdf
February 13, 2007	4	Statement of changes in beneficial ownership of securities	3,4,5	0001179110-07-003591.rtf 0001179110-07-003591.pdf